EGFR and neoplasm: As presented in Table 1, we found that miR-4429 was associated with tumor size (p = 0.033), EGFR mutation (p = 0.006), lymph node metastasis (p = 0.013) and TNM stage (p = 0.002) in NSCLC patients.